About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This BlogEye on FDA is published by Mark Senak of FleishmanHillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
My Favorite Dogs
Category Archives: Pricing and Value
Recently Merck announced a lowering of the price of Zocor (simvastatin) in a move that presumably will put their brand name drug in a competitive position vis a vis an upcoming generic product, just approved by the FDA. This brought … Continue reading
Well, this week is bringing up a lot of memories for me. Today I’m going to share some of them. I already did this once, in a memoir called A Fragile Circle. But a number of years have passed since … Continue reading
Back on April 7, in the posting Clouds on the Horizon, Part I, I wrote about Medicare Part D and the impending donut hole. For those of you who don’t remember, or are new to the blog, the donut hole … Continue reading
There has been a lot of news about generics lately. There are approximately 75 brand name drugs scheduled to go off-patent over the course of the next two years. Last week, the highly lucrative statins saw the first generic among … Continue reading